共 123 条
[1]
Huang HF(2018)The effectiveness of sorafenib over other targeted agents in the second-line treatment of metastatic renal cell carcinoma: a meta-analysis Pathol Oncol Res 10 25-34
[2]
Fan XR(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 19 177-189
[3]
Ji ZG(2019)Sorafenib: key lessons from over 10 years of experience Expert Rev Anticancer Ther 3 42-48
[4]
Cheng AL(2017)Inefficiencies and patient burdens in the development of the targeted cancer drug sorafenib: a systematic review PLoS Biol 192 1620-1627
[5]
Kang YK(2012)Diabetes and risk of renal cell carcinoma J Cancer 194 1554-1560
[6]
Chen Z(2014)Diabetes mellitus is independently associated with an increased risk of mortality in patients with clear cell renal cell carcinoma J Urol 116 1938-1946
[7]
Tsao CJ(2015)Diabetes mellitus as an independent predictor of survival of patients surgically treated for renal cell carcinoma: a propensity score matching study J Urol 12 61-67
[8]
Qin S(2010)Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma Cancer 66 892-896
[9]
Kim JS(2017)Impact of diabetes on outcomes of sorafenib therapy for hepatocellular carcinoma Target Oncol 690 42-50
[10]
Escudier B(2014)The pharmacokinetics and hypoglycaemic effect of sunitinib in the diabetic rabbits Pharmacol Rep 21 15-103